PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Sanofi.

PROGRAM OVERVIEW

The therapeutic landscape for hemophilia is evolving at unprecedented speed. Extended half-life factor replacements, factor mimetics, and rebalancing agents offer clinicians an expanding range of options, while also introducing greater complexity in treatment selection, monitoring, and long-term management.

This 1-hour, CME-certified activity will demonstrate how clinicians can confidently individualize hemophilia care by applying emerging clinical evidence across extended half-life factor replacement therapies, factor VIII mimetics, and rebalancing agents. Expert faculty will lead interactive, case-based discussions that integrate recent evidence with practical considerations such as inhibitor status, bleeding phenotype, monitoring requirements, treatment burden, and patient- and lifestyle-related factors. Through conversational teaching, audience engagement, and real-world scenarios, learners will gain patient-centric guidance to support evidence-informed therapeutic decision-making in contemporary hemophilia practice.

Fine-Tuning the Coagulation Cascade: How We Choose From Expanding Options for Patients With Hemophilia